VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
VERTEX PHARMACEUTICALS INC / MA
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$501.95+2.21 (+0.44%)
Close on Oct 19, 2026
- Market cap
- $128.10B
- P/E (TTM)
- 29.2
- Dividend yield
- –
VERTEX PHARMACEUTICALS INC / MA revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Products | $11.97B | $11.02B | $9.87B | $8.93B | $7.57B | $6.20B | $4.16B | $3.04B | $2.17B | $1.68B | 99.7% | +8.6% |
| TRIKAFTA/KAFTRIO | $10.31B | $10.24B | $8.94B | $7.69B | $5.70B | $3.86B | $420.10M | $0 | – | – | 85.9% | +0.7% |
| ALYFTREK | $837.80M | $0 | $0 | – | – | – | – | – | – | – | 7.0% | – |
| Other CF product revenues | $820.10M | $781.50M | $924.50M | $1.24B | – | – | – | – | – | – | 6.8% | +4.9% |
| CASGEVY | $115.80M | $10.00M | – | – | – | – | – | – | – | – | 1.0% | +1058.0% |
| JOURNAVX | $59.60M | $0 | – | – | – | – | – | – | – | – | 0.5% | – |
| Other revenues | $30.70M | $0 | $0 | $0 | $1.00M | $2.90M | $2.10M | $9.27M | $323.17M | $18.55M | 0.3% | – |
| KALYDECO | – | – | $475.50M | $553.20M | $684.20M | $802.90M | $991.00M | $1.01B | $844.63M | $703.43M | – | – |
| Other | – | – | – | – | – | – | – | $0 | $0 | $610.00K | – | – |
| ORKAMBI | – | – | $326.00M | $510.70M | $771.60M | $907.50M | $1.33B | $1.26B | $1.32B | $979.59M | – | – |
| SYMDEKO/SYMKEVI | – | – | $123.00M | $180.00M | $420.40M | $628.60M | $1.42B | $768.66M | $0 | $0 | – | – |
| TRIKAFTA | – | – | – | – | – | – | $420.11M | $0 | $0 | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $7.55B | $6.68B | $6.04B | $5.70B | – | $4.83B | $3.06B | $2.37B | $1.99B | $1.32B | 62.9% | +12.9% |
| Total long-lived assets outside of the United States | $4.45B | $4.34B | $3.83B | $3.23B | – | $1.38B | $1.10B | $682.52M | $501.87M | $380.37M | 37.1% | +2.7% |
| Europe | $3.46B | $3.45B | $3.11B | $2.71B | – | $1.13B | $885.76M | $543.18M | $420.32M | $320.46M | 28.8% | +0.2% |
| Other | $992.40M | $881.30M | $719.80M | $525.90M | – | $249.94M | $214.50M | $139.34M | $81.55M | $59.91M | 8.3% | +12.6% |
| XX | – | – | – | – | – | – | – | – | $81.55M | $59.91M | – | – |
From the segment and revenue-disaggregation notes of Vertex Pharmaceuticals Inc / Ma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.